Lifescient Inc

Lifescient Inc. is a small company based in South San Francisco, California, with three employees and generating $2.5 million in annual revenue. Lifescient Inc. is dedicated to revolutionizing pet medicine through the development of long-acting injectable (LAI) medications. These innovative medications, administered by veterinarians, provide continuous, controlled drug release for weeks or even months, eliminating the need for daily oral dosing. Lifescient's LAI technology aims to improve the lives of pets by reducing discomfort and enhancing their overall quality of care, while alleviating the daily burden of medication administration for pet owners. The company's lead product, LS-001, is designed to manage pain associated with bone cancer in dogs via a subdermal injection. LS-001 has received a positive response from the Food and Drug Administration (FDA), gaining acceptance of its Investigational New Animal Drug application. Recognizing the product's potential for addressing a significant need in a limited market, the FDA has granted Lifescient a sponsor fee waiver for LS-001 based on its "Minor Use in a Major Species" (MUMS) designation. The company actively pursues a full MUMS designation, which would grant exclusive marketing rights and access to FDA grants for further product development. For more information about Lifescient Inc. and its revolutionary LAI technology, please visit their website at lifescient.com.